Search results

Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and

Type

Technology appraisal guidance

Published

12 August 2020

Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for

Type

Technology appraisal guidance

Published

05 August 2020

Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

01 July 2020

Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic

Type

Technology appraisal guidance

Published

01 July 2020

NICE is unable to make a recommendation on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma, because Janssen did not

Type

Technology appraisal guidance

Published

30 June 2020

NICE is unable to make a recommendation on ramucirumab (Cyramza) with erlotinib for untreated epidermal growth factor receptor (EGFR)-positive metastatic non

Type

Technology appraisal guidance

Published

30 June 2020

NICE is unable to make a recommendation on eculizumab (Soliris) for treating refractory myasthenia gravis because Alexion Pharma UK did not provide an evidence

Type

Technology appraisal guidance

Published

30 June 2020

NICE is unable to make a recommendation about the use in the NHS of ranibizumab (Lucentis) for treating diabetic retinopathy because Novartis did not provide an

Type

Technology appraisal guidance

Published

30 June 2020

Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive

Type

Technology appraisal guidance

Published

24 June 2020

Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia

Type

Medical technologies guidance

Published

24 June 2020

Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults

Type

Technology appraisal guidance

Published

17 June 2020

Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who

Type

Technology appraisal guidance

Published

10 June 2020

Evidence-based recommendations on fremanezumab (Ajovy) for preventing chronic migraine in adults

Type

Technology appraisal guidance

Published

03 June 2020

Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and

Type

Technology appraisal guidance

Published

27 May 2020

Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

13 May 2020

Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months

Type

Technology appraisal guidance

Published

13 May 2020

Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia

Type

Medical technologies guidance

Published

08 April 2020

Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults

Type

Technology appraisal guidance

Published

07 April 2020

Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

Type

Technology appraisal guidance

Last updated

17 March 2020

NICE is unable to make a recommendation on recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals

Type

Technology appraisal guidance

Published

04 March 2020

Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults

Type

Technology appraisal guidance

Published

19 February 2020

Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults

Type

Technology appraisal guidance

Published

13 February 2020

Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2

Type

Technology appraisal guidance

Published

12 February 2020

Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a

Type

Technology appraisal guidance

Last updated

12 February 2020

Evidence-based recommendations on Episcissors-60 for mediolateral episiotomy

Type

Medical technologies guidance

Published

11 February 2020

This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.

Type

NICE guideline

Published

22 January 2020

Evidence-based recommendations on Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C

Type

Medical technologies guidance

Last updated

17 January 2020

Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal

Type

Technology appraisal guidance

Published

15 January 2020

NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC

Type

Technology appraisal guidance

Published

15 January 2020

Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Type

Technology appraisal guidance

Published

15 January 2020

Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure

Type

Technology appraisal guidance

Published

08 January 2020

Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis (RRMS) in adults

Type

Technology appraisal guidance

Published

19 December 2019

Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older

Type

Technology appraisal guidance

Published

18 December 2019

Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome (DS) in people aged 2 years and older

Type

Technology appraisal guidance

Published

18 December 2019

Evidence-based recommendations on gammaCore for cluster headache

Type

Medical technologies guidance

Published

03 December 2019

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema that has inadequately responded to

Type

Technology appraisal guidance

Published

20 November 2019

Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2

Type

Technology appraisal guidance

Published

20 November 2019

Evidence-based recommendations on rucaparib (Rubraca) for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has

Type

Technology appraisal guidance

Published

13 November 2019

Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults

Type

Technology appraisal guidance

Published

13 November 2019

NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults

Type

Technology appraisal guidance

Published

30 October 2019

NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib

Type

Technology appraisal guidance

Published

30 October 2019

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease

Type

Technology appraisal guidance

Published

17 October 2019

Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over

Type

Technology appraisal guidance

Published

16 October 2019

This guideline covers organising and delivering end of life care services, which provide care and support in the final weeks and months of life (or for some conditions, years), and the planning and preparation for this. It aims to ensure that people have access to the care that they want and need in all care settings. It also includes advice on services for carers.

Type

NICE guideline

Published

16 October 2019

Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults

Type

Technology appraisal guidance

Published

09 October 2019

Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing

Type

Medical technologies guidance

Last updated

08 October 2019

Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults

Type

Technology appraisal guidance

Published

02 October 2019

NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults

Type

Technology appraisal guidance

Published

25 September 2019

NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma

Type

Technology appraisal guidance

Published

25 September 2019

NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma

Type

Technology appraisal guidance

Published

25 September 2019